biostudies-literatureGuo ZLEdward Sai Kim Hotung Paediatric Education and Research FundCRCG GrantCancer Institute NSWNational Health and Medical Research Council98https://www.ebi.ac.uk/biostudies/studies/S-EPMC5039880biostudies-literatureUnknown9(1)<h4>Background</h4>Neuroblastoma is a relatively common and highly belligerent childhood tumor with poor prognosis by current therapeutic approaches. A novel anti-cancer agent of the di-2-pyridylketone thiosemicarbazone series, namely di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT), demonstrates promising anti-tumor activity. Recently, a second-generation analogue, namely di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), has entered multi-center clinical trials for the treatment of advanced and resistant tumors. The current aim was to examine if these novel agents were effective against aggressive neuroblastoma in vitro and in vivo and to assess their mechanism of action.<h4>Methods</h4>Neuroblastoma cancer cells as well as immortalized normal cells were usedJournal of hematology & oncologyThe novel thiosemicarbazone, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), inhibits neuroblastoma growth in vitro and in vivo via multiple mechanisms.PMC503988012ECF2-1720000066310373232009071761701060482Richardson DRChan GCGuo ZLTan-Un KCKovacevic ZKalinowski DSfalseThe novel thiosemicarbazone, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), inhibits neuroblastoma growth in vitro and in vivo via multiple mechanisms.<h4>Background</h4>Neuroblastoma is a relatively common and highly belligerent childhood tumor with poor prognosis by current therapeutic approaches. A novel anti-cancer agent of the di-2-pyridylketone thiosemicarbazone series, namely di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT), demonstrates promising anti-tumor activity. Recently, a second-generation analogue, namely di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), has entered multi-center clinical trials for the treatment of advanced and resistant tumors. The current aim was to examine if these novel agents were effective against aggressive neuroblastoma in vitro and in vivo and to assess their mechanism of action.<h4>Methods</h4>Neuroblastoma cancer cells as well as immortalized normal cells were used2016-01-01T00:00:00Z2016 Sep2026-06-08T05:48:26.492Z2019-03-27T02:25:18ZS-EPMC50398802767837210.1186/s13045-016-0330-x